This highly accurate plaque analysis is the foundation for our next-generation CT-derived fractional flow reserve analysis and provides patients and providers with a personalized measure of risk so that their treatment can be tailored to prevent cardiac events like heart attack and stroke.”

Favicon 
elucid.com

Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program - Elucid

Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Associ
Respect!